Ultragenyx Pharmaceutical Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Ultragenyx (RARE) shares rose 7.5% after the FDA approved its gene therapy Genglycos for glycogen storage disease type Ia. The treatment, priced at $2.7M per patient, targets a rare disease affecting 1,500-2,500 Americans. The company reported Q2 revenue of $214M and $436M in cash reserves. Success hinges on patient access and reimbursement.
Ultragenyx Pharmaceutical's Genglycos, a gene therapy for glycogen storage disease type Ia, received FDA accelerated approval on August 19, 2026. Approval was based on reduced cornstarch intake, not hypoglycemia prevention. The therapy showed a 3% increase in hypoglycemic readings. Safety concerns include immune-mediated liver enzyme elevations and adrenal insufficiency. The company's ticker is RARE.
Ultragenyx Pharmaceutical (RARE) gained attention after the FDA granted accelerated approval for its gene therapy, GENGLYCOS, for glycogen storage disease type Ia. The stock rose 2.01% on the news, but is down 3.98% over 30 days and 11.75% over the past year. The company's current price is $25.83, with a fair value estimate of $26.00, suggesting a potential undervaluation. However, risks include higher commercialization costs and ongoing losses.
Over the past 7 days, alphai's AI scored 3 news stories mentioning RARE (Ultragenyx Pharmaceutical Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent RARE coverage spans regulation, market movers and earnings.
In the last 30 days, RARE insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($164K). The most active reporter was Parschauer Karah Herdman, EVP and Chief Legal Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Approval unlocks a $2.7M per‑patient therapy for an ultra‑rare disease, giving Ultragenyx first‑mover status.
First approved therapy targeting the genetic cause of GSDIa, approved on surrogate cornstarch reduction endpoint.
Approval unlocks commercial launch potential and may drive short‑term price upside.
Positive regulatory approval likely lifts RARE shares and supports pipeline momentum.
FDA approval is a major positive event for a biotech.
alphai scores every news story that mentions RARE with an AI model for sentiment and relevance, and aggregates insider trades from Ultragenyx Pharmaceutical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ultragenyx (RARE) shares rose 7.5% after the FDA approved its gene therapy Genglycos for glycogen storage disease type Ia. The treatment, priced at $2.7M per patient, targets a rare disease affecting 1,500-2,500 Americans. The company reported Q2 revenue of $214M and $436M in cash reserves. Success hinges on patient access and reimbursement.
2 min readUltragenyx Pharmaceutical's Genglycos, a gene therapy for glycogen storage disease type Ia, received FDA accelerated approval on August 19, 2026. Approval was based on reduced cornstarch intake, not hypoglycemia prevention. The therapy showed a 3% increase in hypoglycemic readings. Safety concerns include immune-mediated liver enzyme elevations and adrenal insufficiency. The company's ticker is RARE.
3 min readUltragenyx Pharmaceutical (RARE) gained attention after the FDA granted accelerated approval for its gene therapy, GENGLYCOS, for glycogen storage disease type Ia. The stock rose 2.01% on the news, but is down 3.98% over 30 days and 11.75% over the past year. The company's current price is $25.83, with a fair value estimate of $26.00, suggesting a potential undervaluation. However, risks include higher commercialization costs and ongoing losses.
2 min readUltragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readUS futures slide as Treasury yields surge, driven by a rise in Brent oil prices. Key premarket movers include Advance Auto (AAP) down 15%, Alibaba (BABA) down 3%, and Walmart (WMT) down 6%. Cryptocurrency-linked stocks rise as Bitcoin rallies. Sector rotations and elevated yields impact equity markets.
3 min readModerna (MRNA) shares fell 7.7% premarket after a 177% surge following positive trial results for its mRNA cancer vaccine. Five biotech stocks with imminent FDA catalysts are highlighted: Regeneron (REGN), Ultragenyx (RARE), Alnylam (ALNY), Merck (MRK), and Ionis (IONS). Each has recent approvals, upcoming data presentations, or earnings events that could impact their stock prices. Financial metrics and analyst targets are provided for each company. Bitcoin hit $72k after Trump's crypto legislat
3 min readDeere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.
3 min readUltragenyx (RARE) received FDA accelerated approval for GENGLYCOS (DTX401) to treat glycogen storage disease type Ia in patients aged 8+. Clinical studies showed reduced cornstarch reliance and improved glucose regulation. This is Ultragenyx's first gene therapy approval. The stock rose 2.94% to $26.24 on Wednesday and is up 16.45% in pre-market trading.
2 min readUltragenyx Pharmaceutical (RARE) shares rose 14% after the FDA approved GENGLYCOS, a gene therapy for glycogen storage disease type Ia. The approval was based on positive Phase 3 trial results. The company agreed to provide additional safety and efficacy data.
2 min readAnalyst estimates for Ultragenyx Pharmaceutical Inc. show its 12-month average price target cut to $52 from $52.84. The range is $27 to $96 per share, based on 18 analysts. Using the Aug. 13 close, the target implies about 97% upside. The consensus rating remains “Buy” with 16 Buys, 3 Holds, and 0 Sells.
1 min read
